Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%
Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%
Cencora已发布其2025财年全年财务指引，反映了调整后的营业收入增长5%-6.5%和调整后的摊薄后每股收益增长8%-10%
Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
2025财年预期基于调整后（非GAAP）的基础
- Revenue growth to be in the range of 7 to 9 percent;
- U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;
- International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;
- Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.
- 营业收入增长区间为7%至9%；
- 美国医疗保健解决方案部门营业收入增长区间为7%至9%；
- 国际医疗保健解决方案部门营业收入增长区间为7%至9%；
- 调整后的稀释每股收益在14.80美元至15.10美元之间；
Additional expectations include:
其他预期包括：
- Adjusted operating income growth to be in the range of 5 to 6.5 percent;
- U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;
- International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;
- Interest expense to be in the range of $150 million to $170 million;
- Adjusted effective tax rate of approximately 21 percent;
- Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion;
- Capital expenditures to be approximately $600 million; and
- Weighted average diluted shares outstanding to be approximately 196 million.
- 调整后的营业收入增长区间为5%至6.5%；
- 美国医疗保健解决方案部门营业收入增长区间为5%至6.5%；
- 国际医疗解决方案部门营业收入增长率将在5％至6.5％的区间内；
- 利息费用将在15000万至17000万美元的区间内；
- 调整后的有效税率约为21％；
- 调整后的自由现金流将在20亿至30亿美元的区间内；
- 资本支出约为60000万美元；并且
- 加权平均摊薄股份约为19600万。
资讯热榜
更新时间